Harrow Health Inc (HROW) - Financial and Strategic SWOT Analysis Review

November 2021 | 52 pages | ID: H31D4A157DDEN
GlobalData

Abstracts

Harrow Health Inc (HROW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Harrow Health Inc (Harrow Health) formerly known as Imprimis Pharmaceuticals Inc, owns a portfolio of healthcare businesses which also includes ImprimisRx, the leading ophthalmology pharmaceutical compounding business in the US and holds large equity positions in Eton Pharmaceuticals, Melt Pharmaceuticals and Surface Pharmaceuticals. The company is focused on developing innovative medications for serve unmet needs. The company through its subsidiaries develops injectable Dropless Therapy formulations and topical LessDrops formulations. MAY-44 for treating dyspareunia and MAY-88 for treating interstitial cystitis and among others. Harrow Health is headquartered in Nashville, Tennessee, the US.

Harrow Health Inc Key Recent Developments

Nov 09,2021: Harrow Health Announces Third Quarter 2021 Financial Results
Oct 25,2021: Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
Aug 19,2021: Harrow Health announces management change
Aug 12,2021: Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
Aug 10,2021: Harrow Health Announces Second Quarter 2021 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Harrow Health Inc - Key Facts
Harrow Health Inc - Key Employees
Harrow Health Inc - Key Employee Biographies
Harrow Health Inc - Major Products and Services
Harrow Health Inc - History
Harrow Health Inc - Company Statement
Harrow Health Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Harrow Health Inc - Business Description
Business Segment: Pharmaceutical Compounding
Overview
Performance
Business Segment: Pharmaceutical Drug Development
Overview
Performance
Harrow Health Inc - SWOT Analysis
SWOT Analysis - Overview
Harrow Health Inc - Strengths
Harrow Health Inc - Weaknesses
Harrow Health Inc - Opportunities
Harrow Health Inc - Threats
Harrow Health Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Harrow Health Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 09, 2021: Harrow Health Announces Third Quarter 2021 Financial Results
Oct 25, 2021: Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021
Aug 19, 2021: Harrow Health announces management change
Aug 12, 2021: Harrow Health to Participate in Two Upcoming Virtual Investor Conferences
Aug 10, 2021: Harrow Health Announces Second Quarter 2021 Financial Results
Jul 26, 2021: Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021
Jul 15, 2021: Harrow Health granted two patents for novel surgical dilation formulation
May 17, 2021: Leading peer-reviewed ophthalmic journal publishes Study on ImprimisRx’s proprietary klarity-C drops
May 11, 2021: Harrow Health Announces Record First Quarter 2021 Financial Results
Apr 27, 2021: Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Harrow Health Inc, Key Facts
Harrow Health Inc, Key Employees
Harrow Health Inc, Key Employee Biographies
Harrow Health Inc, Major Products and Services
Harrow Health Inc, History
Harrow Health Inc, Subsidiaries
Harrow Health Inc, Key Competitors
Harrow Health Inc, Ratios based on current share price
Harrow Health Inc, Annual Ratios
Harrow Health Inc, Annual Ratios (Cont...1)
Harrow Health Inc, Annual Ratios (Cont...2)
Harrow Health Inc, Interim Ratios
Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Harrow Health Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Harrow Health Inc, Performance Chart (2016 - 2020)
Harrow Health Inc, Ratio Charts
Harrow Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Harrow Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021